Redefining Radial Closure
Pressure only where you need it.
SĀPH (Suction Activated Patent Hemostasis) represents a non-circumferential compression, suction-based approach to radial closure that works with blood flow — not against it.
Developed by a leading interventional cardiologist, SĀPH is designed to support hemostasis while maintaining arterial patency, contributing to smoother procedures, reduced post-procedure workload, and enhanced patient comfort.
By leveraging gentle, controlled suction rather than circumferential pressure, SĀPH is engineered to help address the risk factors associated with radial artery occlusion (RAO) and preserve future access options.
The Compression Problem
Conventional radial closure depends on circumferential or downward pressure to stop bleeding. While effective for hemostasis, this pressure can temporarily collapse the artery and restrict flow — conditions associated with higher RAO rates (reported 1–10% in literature). [1]
In addition, conventional compression devices may:
Require focused nurse monitoring and adjustment. [3]
Result in variability based on user technique.
SĀPH was developed to address these mechanical and workflow limitations through a non-circumferential compression approach.
Why SĀPH Matters
Radial access has become the preferred approach — now used nearly 60% of PCI procedures — but closure technology has not evolved in parallel. [4]
Most available devices still rely on circumferential compression to achieve hemostasis.
SĀPH introduces a suction-based alternative designed to support patent hemostasis, consistent with the 2021 ACC/AHA/SCAI recommendations for preserving radial flow and preventing RAO.
Create patient discomfort or wrist pain (mean discomfort score of 6 out of 10). [2]
Key Advantages: SĀPH is designed to
Support patent hemostasis without circumferential compression
Preserve arterial flow to help maintain future access
Be fully topical — no sutures, implants, or subdermal components
Help reduce pressure-related discomfort
Simplify workflow and minimize staff burden
Evidence at a Glance
“The current hemo static therapies take time and create repetitive tasks from the nursing staff to remove the air. I see that the air removal protocols cannot realistically be followed.
Also, radial artery occlusion is a growing issue. Patients are coming in, sometimes at a young age and your typical CAD patient is going to require multiple caths throughout their lifetime, we hate to lose an access site.”
Bailey Estes
AGNP-C, MSN; Cardiac Cath Lab Scrub Nurse and Researcher; Co-Chair of the ACC Cardiovascular Team Communications Work Group; Cath Lab Digest Editorial Board Greater Abilene Area
About us
Transradial Technologies, Inc. is a medical device company focused on developing a novel, minimally invasive transradial vascular closure device.
Transradial Technologies, Inc. has worldwide and exclusive rights to the technology via an agreement with Transradial Holdings, Inc.
